摘要
心力衰竭(HF)是急性心肌梗死后的严重并发症,尽管目前治疗手段众多,但病死率仍居高不下。近年来,沙库巴曲缬沙坦的出现为心血管疾病领域的治疗带来突破性进展,作为一种新型血管紧张素受体-脑啡肽酶抑制剂,已被列为治疗慢性HF的一线药物,随着在心肌梗死、高血压、糖尿病和肾脏疾病等方面的研究广泛展开,其更多的临床益处被发现。本文主要探讨沙库巴曲缬沙坦在治疗急性心肌梗死后HF中的应用进展。
Heart failure is a serious complication after acute myocardial infarction and has a high mortality rate despite numerous treatments at present.In recent years,the emergence of sacubitril valsartan has brought breakthrough progress in the treatment of cardiovascular diseases.As a novel angiotensin receptor-neprilysin inhibitor,it has been listed as the first-line drugs for the treatment of chronic heart failure.With the increasing research on myocardial infarction,hypertension,diabetes,and kidney disease,more clinical benefits of sacubitril valsartan have been discovered.This article mainly discusses the application progress of sacubitril valsartan in the treatment of heart failure after acute myocardial infarction.
作者
李云曌
吴辉
刘滴
周刚
LI Yunzhao;WU Hui;LIU Di;ZHOU Gang(Institute of Cardiovascular Diseases,China Three Gorges University&Department of Cardiology,Yichang Central People’s Hospital,Yichang,Hubei,443003,China)
出处
《临床心血管病杂志》
CAS
北大核心
2021年第1期12-15,共4页
Journal of Clinical Cardiology
基金
国家自然科学基金青年项目(No:81600234)
宜昌市医疗卫生研究项目(No:A20-2-001)。
